Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET-MS study of autologous hematopoietic stem cell transplantation versus high-efficacy disease-modifying therapy in aggressive relapsing-remitting multiple sclerosis
2024-515470-26-00Phase 2Completed
- Sponsor
- Fondazione Italiana Sclerosi Multipla
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous hematopoietic stem cells, natalizumab, alemtuzumab, ocrelizumab and ublituximab in multiple sclerosis (MS) (2 arms), sponsored by Fondazione Italiana Sclerosi Multipla. Primary endpoint: Any evidence of multiple sclerosis disease activity (NEDA-3). Started Dec 2024; status: completed.
02
Drugs
autologous hematopoietic stem cellsnatalizumabalemtuzumabocrelizumabublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-515470-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515470-26-00.